
A report authored by over 100 oncologists noted that of the twelve new cancer drugs approved in 2012, eleven were priced above $100,000 a year! These doctors conclude that the prices of many of these drugs “ are too high, unsustainable, may compromise access of needy patients to highly effective therapy, and are harmful to the sustainability of our national healthcare systems .” These revelations from inside the cancer establishment will not surprise Life Extension members, who long ago learned how regulatory strangleholds over drug development inflict harsh economic pain.
Apr 1, 2025

A report authored by over 100 oncologists noted that of the twelve new cancer drugs approved in 2012, eleven were priced above $100,000 a year! These doctors conclude that the prices of many of these drugs “ are too high, unsustainable, may compromise access of needy patients to highly effective therapy, and are harmful to the sustainability of our national healthcare systems .” These revelations from inside the cancer establishment will not surprise Life Extension members, who long ago learned how regulatory strangleholds over drug development inflict harsh economic pain.
Apr 1, 2025

A report authored by over 100 oncologists noted that of the twelve new cancer drugs approved in 2012, eleven were priced above $100,000 a year! These doctors conclude that the prices of many of these drugs “ are too high, unsustainable, may compromise access of needy patients to highly effective therapy, and are harmful to the sustainability of our national healthcare systems .” These revelations from inside the cancer establishment will not surprise Life Extension members, who long ago learned how regulatory strangleholds over drug development inflict harsh economic pain.
Apr 1, 2025
Trending Now
Subscribe To Us
Subscribe For Our Latest News & Updates

















